ASCO 2019: Patients who received PBI without chemotherapy experienced less fatigue, slightly poorer cosmesis
Patient-reported outcome (PRO) data indicates that partial breast irradiation (PBI) is more convenient than whole…
Browsing: ASCO 2019
ASCO 2019: Men who choose active surveillance for early prostate cancer often don’t follow monitoring rules
Preliminary results from a University of North Carolina Lineberger Comprehensive Cancer Center study found that…
ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung cancer
A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients…
ASCO 2019: Colorectal cancer patients with liver metastases live just as long after laparoscopic surgery as open surgery
The randomised OSLO-COMET trial found that laparoscopic surgery did not change chances of survival, when…
ASCO 2019: Novel targeted-antibody treatment produced responses in nearly half of patients with advanced urothelial cancer
A single arm, phase II clinical trial of 125 patients showed treatment with enfortumab vedotin…
ASCO 2019: NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction…
ASCO 2019: NRG oncology trial of metformin for non-small cell lung cancer
Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients,…
ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer
Immunotherapy used with chemotherapy or on its own is a better first-line treatment for people…
ASCO 2019: Earlier ovarian cancer diagnoses and treatment seen after ACA implementation
An analysis of data from the National Cancer Database found that after implementation of the…
ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone-sensitive prostate cancer
An interim analysis of the international randomised, phase III ENZAMET trial found that 80% of…